Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report suggests that scalp arteriovenous malformations can cause local hair loss, which may recover following ethanol embolization treatment.

This study concluded that etretinate showed only moderate effects in treating lichen sclerosus and localized scleroderma, with some patients experiencing clearing but others having no resolution or lesion progression.

In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.

This study found that scalp micropigmentation was a safe and effective cosmetic solution for localized alopecia, showing significant improvement in visual density and high patient satisfaction without adverse events.

This comparative clinical study found no statistically significant difference in the remission and recurrence rates between intralesional triamcinolone acetonide and methotrexate for treating localized alopecia areata, suggesting similar efficacy between the two treatments.

This study found that garlic gel significantly improved the efficacy of topical betamethasone valerate in treating alopecia areata compared to placebo.

This study found that long-term use of difluprednate ophthalmic emulsion in dogs can lead to HPA axis suppression and potentially cause iatrogenic hyperadrenocorticism, with localized alopecia suspected due to dermal absorption.

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.

This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.

This letter discusses the use of serial trichoscopy versus a modified hair pull test for monitoring localized alopecia areata but reports no new clinical results.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This study found that long-term imiquimod treatment on mice intensified skin inflammation early on, but topical corticosteroids significantly reduced skin infiltration and inflammatory cytokines after initial inflammation subsided.

This study found that intralesional triamcinolone was more effective than the 308 nm Excimer laser in achieving >75% hair regrowth in patients with localized alopecia areata over 12 weeks.

This study reported that both topical methotrexate 1% gel and minoxidil 5% gel were effective in treating localized alopecia areata, with no significant differences in efficacy between the two treatments.

In this study, both methotrexate gel and betamethasone lotion were found to be effective and safe treatments for localized alopecia areata, with similar overall response rates. However, methotrexate gel had a higher incidence of local side effects, such as irritant dermatitis and itching.

In this case report, a 34-year-old man experienced temporary hair loss after undergoing an endovascular procedure with fluoroscopy for facial arteriovenous malformation, which resolved within two months following treatment with topical Minoxidil and oral Cilostazol.

This case study describes the successful management of alopecia areata in an 18-year-old female patient using Shaman Aushadhi.

In this study, single hair grafting was reported to be an effective treatment for localized/segmental vitiligo, notably in hairy skin areas, with repigmentation observed in 82% of those cases.

In this randomized controlled trial, intralesional vitamin D3 injections significantly improved localized alopecia areata symptoms compared to a saline placebo, with minimal and transient side effects, suggesting vitamin D3 as an effective treatment option without needing prior serum vitamin D level measurement.

This study found that autologous platelet-rich plasma significantly improved hair follicle number, thickness, and density in patients with androgenic alopecia compared to placebo, with high reported patient satisfaction.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This study found that intralesional triamcinolone was more effective than topical betamethasone for hair regrowth in patients with localized alopecia areata.

This clinical trial found that hemp seed oil may be a promising treatment for localized alopecia areata, with notable hair regrowth observed in some patients after eight weeks of use.

This study found that platelet-rich plasma may effectively increase hair follicle numbers in men with androgenetic alopecia, but changes in hair thickness plateaued after the second injection.

The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.

This review examines the use of microneedles for treating alopecia areata, highlighting their ability to enhance drug delivery through the skin by bypassing the outer barrier and promoting hair growth with minimal invasiveness.

This review summarizes drug delivery strategies to hair follicles, highlighting physicochemical factors affecting penetration and the use of stimuli-responsive particulate carriers, but reports no new clinical findings.

This review discusses the enhancement of drug penetration through hair follicles and reports no new clinical results while noting the potential for future research on controlled drug release methods.

This study found that localized administration of heat or certain stress protein inducers effectively prevented chemotherapy-induced hair loss in rodent models without affecting chemotherapy efficacy.